CD44 Antibody (P3H9): sc-53505
- CD44 Antibody (P3H9) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against HT-1080 fibrosarcoma cells of human origin
- recommended for detection of HCAM of human origin by WB, IP and IF
- See CD44 (DF1485): sc-7297 for CD44 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD44 Antibody (P3H9) for WB applications. These reagents are now offered in bundles with CD44 Antibody (P3H9) (see ordering information below).
QUICK LINKS
SEE ALSO...
HCAM Antibody (P3H9) is a mouse monoclonal IgG1 antibody that detects HCAM in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). HCAM, also known as CD44, LHR, MDU2, MDU3, MIC4, Pgp1, HCELL, MUTCH-I, or ECMR-III, is a 742 amino acid single-pass type I membrane protein that plays a crucial role in hematopoiesis, lymphocyte activation, and tumor metastasis. HCAM functions primarily as a receptor for hyaluronic acid (HA) and interacts with ligands such as osteopontin (OPN), facilitating essential cell-cell and cell-matrix interactions that are vital for cell adhesion and migration. HCAM is characterized by one Link domain and undergoes alternative splicing to produce multiple isoforms, including CD44R, CDw44, CD44S, CD44H (hematopoietic), and CD44E (epithelial). CD44H isoform is expressed at elevated levels in cancer tissues, indicating significant involvement in tumor progression and highlighting HCAM′s importance in cancer biology. Anti-HCAM antibody (P3H9) serves as an invaluable tool for researchers studying cell adhesion and migration dynamics in various biological contexts, particularly in cancer research.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD44 Antibody (P3H9) References:
- HAS2 and CD44 in breast tumorigenesis. | Heldin, P., et al. 2014. Adv Cancer Res. 123: 211-29. PMID: 25081531
- Interactions between CD44 and Hyaluronan in Leukocyte Trafficking. | McDonald, B. and Kubes, P. 2015. Front Immunol. 6: 68. PMID: 25741341
- Modulation of CD44 Activity by A6-Peptide. | Finlayson, M. 2015. Front Immunol. 6: 135. PMID: 25870596
- Involvement of hyaluronan and CD44 in cancer and viral infections. | Heldin, P., et al. 2020. Cell Signal. 65: 109427. PMID: 31654718
- Proteolytic Processing of CD44 and Its Implications in Cancer. | Medrano-González, PA., et al. 2021. Stem Cells Int. 2021: 6667735. PMID: 33505471
- The CD44/COL17A1 pathway promotes the formation of multilayered, transformed epithelia. | Kozawa, K., et al. 2021. Curr Biol. 31: 3086-3097.e7. PMID: 34087104
- Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells. | Yi, P., et al. 2023. Clin Immunol. 255: 109710. PMID: 37499961
- A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy. | Freitas, R., et al. 2024. J Control Release. 367: 540-556. PMID: 38301927
- CD44 in colon cancer. | Herrlich, P., et al. 1995. Eur J Cancer. 31A: 1110-2. PMID: 7577002
- Expression of CD44 (HCAM) in small lymphocytic and mantle cell lymphoma. | Aguilera, NS., et al. 1998. Hum Pathol. 29: 1134-9. PMID: 9781654
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD44 Antibody (P3H9) | sc-53505 | 200 µg/ml | $322.00 | |||
CD44 Antibody (P3H9): m-IgGκ BP-HRP Bundle | sc-534154 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD44 Antibody (P3H9): m-IgG1 BP-HRP Bundle | sc-538860 | 200 µg Ab; 20 µg BP | $361.00 |